Recommendation of the President – Lynparza (olaparibum)
On 03June 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 54/2022 of 3 June 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the inclusion in the reimbursement procedure of the medicinal products Lynparza, olaparibum, film-coated tablets, 150 mg, 56 tablets, GTIN 05000456031318 and Lynparza, olaparibum, film-coated tablets, 100 mg, 56 tablets, GTIN 05000456031325, under the new treatment programme “Treatment of patients with metastatic or ineligible for radical treatment pancreatic adenocarcinoma with BRCA 1/2 gene mutations” (ICD-10 C25.0, C25.1, C25.2, C25.3, C25.5, C25.7, C25.8, C25.9) (ICD-10 C25.0, C25.1, C25.2, C25.3, C25.5, C25.7, C25.8, C25.9)